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Abstract
Background: Dysferlinopathies are a group of muscle disorders causing muscle weakness and absence or low
levels of dysferlin, a type-II transmembrane protein and the causative gene of these dystrophies. Dysferlin is
implicated in vesicle fusion, trafficking, and membrane repair. Muscle biopsy of patients with dysferlinopathy is
characterized by the presence of inflammatory infiltrates. Studies in the muscle of both human and mouse models
of dysferlinopathy suggest dysferlin deficient muscle plays a role in this inflammation by releasing thrombospondin-
1. It has also been reported that vitamin D3 treatment enhances dysferlin expression. The ubiquitin-proteasome
system recognizes and removes proteins that fail to fold or assemble properly and previous studies suggest that its
inhibition could have a therapeutic effect in muscle dystrophies. Here we assessed whether inhibition of the
ubiquitin proteasome system prevented degradation of dysferlin in immortalized myoblasts from a patients with
two missense mutations in exon 44.
Methods: To assess proteasome inhibition we treated dysferlin deficient myotubes with EB1089, a vitamin D3
analog, oprozomib and ixazomib. Western blot was performed to analyze the effect of these treatments on the
recovery of dysferlin and myogenin expression. TSP-1 was quantified using the enzyme-linked immunosorbent
assay to analyze the effect of these drugs on its release. A membrane repair assay was designed to assess the ability
of treated myotubes to recover after membrane injury and fusion index was also measured with the different
treatments. Data were analyzed using a one-way ANOVA test followed by Tukey post hoc test and analysis of
variance. A p ≤ 0.05 was considered statistically significant.
Results: Treatment with proteasome inhibitors and EB1089 resulted in a trend towards an increase in dysferlin and
myogenin expression. Furthermore, EB1089 and proteasome inhibitors reduced the release of TSP-1 in myotubes.
However, no effect was observed on the repair of muscle membrane after injury.
Conclusions: Our findings indicate that the ubiquitin-proteasome system might not be the main mechanism of mutant
dysferlin degradation. However, its inhibition could help to improve muscle inflammation by reducing TSP-1 release.
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Background
Mutations in the dysferlin gene (DYSF) that lead to ab-
sence or marked reduction of the protein are the cause
of dysferlinopathy [1]. The disease is an autosomal reces-
sive muscle disorder and has several phenotypes, includ-
ing limb girdle 2B [2], Miyoshi myopathy [3] and distal
anterior compartment myopathy [4]. Progression of the
disease is characterized by muscle weakness and atrophy,
and muscle biopsy shows mainly necrosis of muscle fibers
and inflammatory infiltrates. Although several genetic and
pharmacologic treatments have been tested [5, 6], no
curative treatment is yet available for dysferlinopathy [7].
DYSF contains 55 exons and 14 isoforms. Fifty-three
percent of patients have nonsense mutations, 43% have
missense mutations, and 4% have small in-frame inser-
tions or deletions [1]. While nonsense mutations pro-
duce a complete absence of the protein, a residual
expression of dysferlin is detected in primary myotubes
from patients carrying missense mutations [8, 9].
Dysferlin protein is highly expressed in skeletal muscle,
cardiac muscle and blood monocytes [10]. It is a type-II
transmembrane protein that contains seven C2 domains
(Ca2+-binding) involved in vesicle fusion, trafficking,
membrane repair and regulation of calcium homeostasis
[11, 12]. However, it is also associated with other pro-
cesses, including intracellular signaling and myoblast dif-
ferentiation [13]. Studies using primary cultures of human
skeletal muscle show that dysferlin and myogenin may
share a pathway involved in differentiation of skeletal
muscle “in vitro” as dysferlin-deficient (dysf mut/mut)
myotubes have reduced expression of myogenin and are
poorly differentiated [14]. It has been reported that
thrombospondin-1 (TSP-1) expression is increased in dysf
mut/mut myotubes and may play a role in the inflamma-
tion observed in muscle biopsies of patients with dysferlin
myopathy [15]. In fact, it has been shown that serum TSP-
1 levels correlate with macrophage inflammation and
muscle damage in dysferlin-deficient BlaJ mice [16].
The ubiquitin-proteasome system (UPS) is the major
proteolytic pathway as more than 80% of cellular pro-
teins are degraded therein [17]. The UPS is an ATP-
dependent system that removes unfolded or misfolded
proteins [18]. It interacts only with proteins labelled with
a polyubiquitin chain [18]. Proteins bind proteasome
through the α-rings of the 20S subunit and then pass
through the β-rings, where they are degraded by the pro-
teasome particles: chymotrypsin-like (CT-L), caspase-
like (C-L), and trypsin-like (T-L) proteolytic sites [19].
Previous studies have shown that proteasome inhibitors
could have a therapeutic implication in muscle dystrophies.
It has been reported that the proteasome inhibitor MG-132
rescued the expression of the dystrophin-glycoprotein com-
plex (DGC) in mouse models of Duchenne muscular dys-
trophy and in skeletal muscle cultures from patients with
Duchenne and Becker muscular dystrophy [20–22].
Bortezomib, another proteasome inhibitor, promoted
the expression and membrane localization of dys-
trophin and dystrophin-associated proteins in mdx
mice, but the drug had only a modest effect in myo-
blasts from patients with DMD [22]. Since patients
carrying missense mutations in DYSF have residual ex-
pression of dysferlin, prevention of its degradation by
the UPS could be used as a therapeutic approach.
Apart from avoiding protein degradation, other studies
have focused on increasing dysferlin expression by acti-
vating gene expression. In peripheral blood monocytes
(PBM) and myotubes of dysferlinopathy carriers bearing
one mutation in DYSF, dysferlin expression is increased
after vitamin D3 treatment [8]. Vitamin D3 binds to the
vitamin D3 response element (VDRE) present in the dys-
ferlin promoter and enhances dysferlin expression.
EB1089 is an analogue of vitamin D3 that shows higher
efficacy and less hypercalcemic activity [23], but its effect
on dysferlin expression has not been studied.
As there are no effective treatments for dysferlinopa-
thies, we assessed whether inhibition of the ubiquitin
proteasome system could prevent degradation of dysfer-
lin in immortalized myoblasts from a patient carrying
two missense mutations. We used oprozomib and ixazo-
mib, 2 s generation proteasome inhibitors that have re-
duced toxicity and off-targets, increasing effectiveness.
We also studied the role of EB1089 in the expression of
dysferlin, alone or in combination with proteasome in-
hibitor. We evaluated the effect of these treatments by
studying the expression of myogenin, the ability of myo-




In all experiments we used immortalized myoblasts from
a dysferlinopathy patient with homozygous missense
mutations (c.4882G > A/p.G1628R) in exon 44 of DYSF
and from a healthy control. This patient corresponds to
number 16 in our previous work and was described
showing some degree of dysferlin expression in sarco-
plasm [24]. These cells present a residual expression of
dysferlin of about 1–2% compared to WT myotubes.
These cells were kindly provided by Dr. Mouly [25].
Myoblasts were expanded using skeletal muscle medium
(SMM; Promocell, Heidelberg, Germany) until confluence
was achieved. Media was then changed to differentiation
medium (75% Dulbecco’s Modified Eagle’s Medium and
25% M199, supplemented with 2% FBS (Lonza, Basel,
Switzerland), 10 μg/ml insulin (Sigma-Aldrich, St Louis,
MO, USA), 2mmol/l glutamine (Lonza) and penicillin-
streptomycin (Lonza)) for 7 to 9 days. Differentiated myo-
tubes were treated with vitamin D3 or EB1089 (Sigma
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Aldrich) at 100 nM, ixazomib (Selleckchem, Munich,
Germany) (25 nM, 50 nM and 100 nM) and oprozomib
(ONX 0912)(Selleckchem) (10 nM, 50 nM and 100 nM).
Ixazomib and oprozomib were combined with EB1089 at
8 h and 24 h, respectively.
Western blot
Cell pellets corresponding to each condition were lysed
in RIPA buffer (Sigma-Aldrich) containing a protease
and phosphatase inhibitor cocktail (Roche, Basel,
Switzerland). Lysates were centrifuged at 4 °C at 13000 x
g for 20 min and supernatants were stored at − 80 °C.
Protein concentrations were determined using Pierce™
BCA Protein Assay (Thermo Fisher Scientific, Waltham,
MA, USA). Thirty micrograms of protein were resolved
in a 10% sodium dodecyl sulfate (SDS) polyacrylamide
gel and transferred to nitrocellulose membranes. Unspe-
cific binding sites were blocked by incubation for 1 h in
casein diluted 1:1 in tris-buffered saline (TBS). Blots
were incubated overnight with the primary mouse
monoclonal antibodies anti-dysferlin (NCL-Hamlet,
Novocastra, Newcastle, UK) and anti-myogenin (5FD
clone) (Santa Cruz Biotechnology, Dallas, TX). To
normalize the results, mouse anti-desmin (Novocastra)
was added simultaneously with the primary antibody.
The secondary antibody for anti-dysferlin was a goat
anti-mouse labeled with IR-Dye 800 (Li-Cor, Lincoln,
Nebraska, USA). When the anti-myogenin antibody was
used as a primary antibody, biotin-labeled horse anti-
mouse (Jackson ImmunoResearch, Ely, UK) was used as
a secondary antibody. Secondary antibodies were incu-
bated for 1 h at room temperature. Membranes incu-
bated with biotinylated secondary antibody were washed
and incubated for 1 h with IRDye-680-labeled streptavi-
din (Li-Cor). After extensive washing, the immunoreac-
tive bands were visualized using the Odyssey Infrared
ImagingSystem (Li-Cor). The amount of protein was
quantified using Image Studio Lite software (Li-Cor).
Desmin expression was used as a loading control. As a
reference value we used dysferlin or myogenin expres-
sion of the healthy control. Protein expression in the
remaining conditions was quantified over the expression
in WT myotubes and expressed as fold-change.
Assessment of proteasome-like activity
Cells were seeded in a 96- well black plate (Sarstedt,
Nümbrecht, Germany) at 5000 cells/well in 3 replicates
until confluence. The media was then changed to differ-
entiation medium. Cells were treated with the corre-
sponding drug for the indicated time. The CT-L, C-T
and T-L activity was assayed by chemiluminiscence
using the Proteasome-Glo™ 3-substrate System cell based
assay (Promega, Madison, WI, USA) and the plate was
read using Victor 3v Multilabel Plate Reader (Perkin
Elmer, Waltham, MA, USA).
Thrombospondin-1 Enzyme-Linked Immunosorbent Assay
(ELISA)
Immortalized myoblasts from the dysferlinopathy patient
were seeded at 5000 cells/cm2 and expanded until con-
fluence. The media was then changed to differentiation
medium to form myotubes. After treatment with prote-
asome inhibitors together with or without EB1089, we
removed the media and added 1ml of basal DMEM
(Lonza) to the culture for 24 h. Cell culture supernatants
were concentrated using Amicon Ultra Centrifugal Filters
100 kb (Merck Millipore, Darmstadt, Germany). TSP-1
present in the culture media was detected using the human
TSP-1 Immunoassay (Quanti-Kine ELISA, R&D Systems,
Minneapolis, MN), following the manufacturer’s instruc-
tions. The detection limit of the assay was 0.355 ng/mL.
Membrane repair assay
Immortalized myoblasts from the dysferlinopathy patient
and the healthy control were grown until confluence in
chambered wells and then differentiated to myotubes.
The assay was performed as recently described in human
muscle primary cultures [26]. SDS is an anionic surfac-
tant that causes the leakage of intracellular components
due to its ability to affect membranes [27]. Membrane
injury was induced by detergent treatment as follows:
after the cell cultures were washed with Hank’s Balanced
Salt Solution (HBSS) (Lonza), the injury solution (HBSS
with 0.12 mM or 0.25 mM SDS (Sigma-Aldrich)) was ap-
plied for 2 min. Following exposure to injury solution,
cells were washed in HBSS and then incubated in recov-
ery solution consisting of proliferation media for 90 s
and 10min. The injury and recovery steps were per-
formed at 37 °C. Cells with injured permeable mem-
branes were identified by exposure to propidium iodide
(PI) (Sigma-Aldrich) (20 μg/mL in HBSS). If cell mem-
brane is not repaired, PI enters the cell and penetrates
the nucleus wherein it intercalates with DNA and emits
fluorescence. After 2 min of exposure to the dye, cells
were washed with HBSS and fixed with 4% paraformal-
dehyde in PBS. Nuclei were stained with Hoescht 33,342
(Invitrogen, Thermo-Fisher Scientific). In each experi-
mental condition, we counted the total number of nuclei
and the PI positive nuclei using Fiji software [28].
Fusion index
Once membrane repair assay was performed, myotubes
were permeabilized with ethanol for 5 min at room
temperature. Samples were then blocked with the Ultra-
Cruz Blocking Reagent (Santa Cruz Biotechnology,
Dallas, TX) for 1 h at RT. Myotubes were stained using a
mouse anti-myosin heavy chain (MyHC) antibody (MF-
Fernández-Simón et al. BMC Musculoskeletal Disorders          (2020) 21:784 Page 3 of 10
20)(Bio-Rad, Hercules, CA, USA) for 1 h at RT and then
the goat anti-mouse secondary antibody Alexa Fluor 594
(ThermoFisher, Wal- tham, MA) was used as a secondary
antibody for 1 h at RT. Following the incubation with the
secondary antibody, nuclei were stained with Hoescht
3342 (Invitrogen, Thermo-Fisher Scientific). Images were
acquired and analysed using Fiji software.
The fusion index was determined as the percentage of
nuclei included in MF-20-expressing myotubes (contain-
ing at least 3 nuclei) divided by the total number of nuclei.
Statistical analysis
Multiple comparisons were analyzed using a one-way
ANOVA test followed by Tukey post hoc test. When
statistical comparisons were performed between two
groups, the nonparametric Mann-Whitney test was used.
GraphPad Prism 5.0 software was used (LaJolla, CA,
USA) for graphic representation.
Results
EB1089 and vitamin D3 treatment
Vitamin D3 and EB1089 were added to healthy control
myotubes for 24 h at 100 nM in order to assess their ef-
fect on dysferlin expression. Both Vitamin D3 and
EB1089 increased dysferlin expression. However, only
treatment with EB1089 showed statistically significant
differences compared to non-treated myotubes (Fig. 1).
Therefore, from this point on, we decided to use EB1089
in combination with proteasome inhibitors to increase
dysferlin expression.
Proteasome inhibition
We analyzed the time points at which ixazomib and opro-
zomib produced the highest increase in dysferlin expres-
sion in dysf mut/mut myotubes. The effect of ixazomib
was highest at 8 h and the effect of oprozomib was highest
at 24 h (data not shown). We also analyzed whether the
addition of EB1089 to the proteasome inhibitors had an
effect on dysferlin expression at the same time points.
Treatment of dysf mut/mut myotubes with 10 nM
oprozomib for 24 h showed high selectivity towards the
CT-L active site of the proteasome. However, at higher
doses (50 nM and 100 nM) oprozomib also inhibited C-
L and T-L activity significantly (Fig. 2a-c).
Ixazomib treatment inhibited all 3 proteasome sub-
units (Fig. 2d-f).
When EB1089 was added alone to the culture, no pro-
teasome inhibition in any subunit was found. Moreover,
when it was combined with ixazomib and oprozomib, no
effect was observed in the inhibition of each subunit of
the proteasome.
Dysferlin and myogenin expression
We analyzed the expression of dysferlin and myogenin
in dysf mut/mut myotubes treated with EB1089, oprozo-
mib and ixazomib.
Fig. 1 Effect of Vitamin D3 and EB1089 on healthy control myotubes. a Quantification of WB bands of untreated wild-type myotubes (C- ),
Vitamin D3 and EB1089 treated wild-type myotubes for 24 h. Vitamin D3 treatment produced an increase in dysferlin expression compared to
non-treated myotubes. However, only EB1089 showed a significant increase compared to non-treated myotubes. b Representative WB of dysferlin
with vitamin D3 and EB1089 treatment. Desmin was used as a loading control. Data are represented as mean of 3 replicates ± standard deviation.
Fold-change is calculated over the results of dysferlin expression in non-treated WT myotubes. Results were statistically analyzed using one-way
Anova followed by Tukey post hoc test. Statistical significance was set at p < 0.05. *p < 0.05
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Treatment with oprozomib at 24 h showed a trend to-
wards an increase in myogenin expression (Fig. 3a-b).
When EB1089 was added together with oprozomib, myo-
genin presented a trend towards decreased expression
compared to oprozomib treatment alone. Dysferlin pre-
sented a trend towards increased expression with 10 nM
of oprozomib with and without EB1089. No statistical sig-
nificances were observed in any experimental conditions.
Treatment with ixazomib (Fig. 3c-d) showed no sig-
nificant increase in the expression of dysferlin. Myogenin
levels showed a trend towards increased expression after
ixazomib treatment, being 100 nM the concentration at
which the myogenin expression was the highest. The
addition of EB1089 together with ixazomib presented a
trend towards decreased expression of myogenin com-
pared to ixazomib treatment alone, but the results did
not reach statistical significance.
Expression of TSP-1
We evaluated the secretion of TSP-1 by dysf mut/mut
myotubes treated with EB1089, oprozomib and ixazo-
mib. Treatment with EB1089 significantly reduced TSP-
1 release at 8 h. TSP-1 levels also decreased significantly
in dysf mut/mut cells treated with oprozomib and
EB1089 separately (Fig. 4a). TSP-1 levels decreased even
more significantly when cells were treated with the com-
bination of EB1089 and oprozomib.
Ixazomib treatment significantly decreased TSP-1 only
when combined with EB1089 (Fig. 4b). However, al-
though EB1089 and ixazomib alone did not produce
significant changes in TSP-1 expression, expression was
lower than in untreated myotubes.
Raw western-blot data are available in Supplementary
Figure 1.
Sarcolemma repair assay
Considering that dysferlin is involved in membrane re-
pair after injury, we analyzed the ability of dysf mut/mut
myotubes, treated with proteasome inhibitors and
EB1089, to repair the sarcolemma after injury. We found
that wild-type myotubes repaired the membrane at both
low and high concentration of SDS (0.12 mM SDS and
at 0.25 mM SDS), showed by PI exclusion, 10 min after
injury (Fig. 5a). However, dysf mut/mut myotubes did
Fig. 2 Proteasome inhibition profile. The three distinct ATPase-independent proteolytic activities (CT-L, C-L and T-L) of the proteasome were
assayed using a chemioluminiscence-based method. Dysf mut/mut myotubes were pretreated with oprozomib and EB1089 for 24 h. Oprozomib
treatment presented inhibition at: a CT-L at all concentrations tested b) C-L, and c) T-L activity also were inhibited by oprozomib, but only at
high doses (50 nM and 100 nM). Pre-treatment with ixazomib and EB1089 for 8 h was also assayed and d) CT-L, e) C-L and f) T-L activity were
inhibited at all doses tested with significant differences. Data are represented as mean of 3 replicates ± standard deviation. Results were statistically
analyzed using one-way Anova followed by Tukey post hoc test. Statistical significance was set at p < 0.05. *p < 0.05; **p < 0.01; ***p < 0.0001
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not present any sarcolemma repair in any condition
tested (Fig. 5a-c).
Fusion index
Fusion index results showed that dysf mut/mut myotubes
presented a statistically significant lower fusion index
compared to wild-type myotubes (Fig. 5e). Ixazomib,
oporozomib and EB1089 did not show any effect on the
fusion index of dysf mut/mut myotubes (Fig. 5f-g).
Discussion
The aim of this study was to test if blockade of prote-
asome could restore dysferlin expression and conse-
quently rescue the muscle functions that are impaired
when dysferlin is missing. It has been reported that dys-
ferlin deficient myoblasts display reduced levels of myo-
genin and consequently fusion index is reduced [14].
Muscles biopsies of dysferlinopathy patients are charac-
terized by the presence of abundant inflammatory infil-
trates [29], TSP-1 seems to have a prominent role in
muscle inflammation in this pathology [15]. Finally, dys-
ferlin is involved in sarcolemma repair [26, 30].
Treatment with oprozomib, ixazomib and EB1089 in
myotubes from a dysferlinopathy patient promoted a
trend towards increased expression of dysferlin and
myogenin, but this low increase did not translate into
higher sarcolemmal repair neither higher fusion index
than that in untreated myotubes. However, TSP-1 re-
lease from myotubes decreased after treatment.
Western blot analysis showed a trend towards in-
creased expression of dysferlin and myogenin when
oprozomib and EB1089 were added to the culture. Ixa-
zomib produced a trend towards increased expression
of myogenin but not dysferlin. These results are in
agreement with a previous work by Fujita E et al. They
found that mutant-dysferlin was mainly degraded by au-
tophagy while wild type-dysferlin was degraded by the
ubiquitin-proteasome system, although they used a pro-
teasome inhibitor different from those used in this study
[31]. The small increase in dysferlin expression that we
observed after treating dysf mut/mut myotubes with our
different ubiquitin-proteasome inhibitors confirms that
this system is not the main pathway to recycle mutated
dysferlin.
Fig. 3 Dysferlin and myogenin expression in dysf mut/mut muscle cells. a Representative WB of myogenin and dysferlin with oprozomib and
EB1089 treatment. C+: untreated wild-type myotubes, (C-) untreated dysf mut/mut myotubes. Desmin was used as loading control. b
Quantification of WB bands of dysferlin or myogenin expression. The highest expression of dysferlin and myogenin was reached using oprozomib
at 10 nM. c Representative WB of myogenin and dysferlin with ixazomib and EB1089. d Quantification of WB showed that 100 nM of ixazomib
presented the highest expression of dysferlin and myogenin. Data are represented as the mean of 3 replicates ± standard deviation. The fold-
change is calculated over the results of dysferlin expression in WT non-treated myotubes. Results were statistically analyzed using one-way Anova
followed by Tukey post hoc test. Statistical significance was set at p < 0.05
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The other treatment that we studied, the analogue of
Vitamin D3, EB1089, produced a trend towards increased
expression of dysferlin. In other studies, authors found
that Vitamin D3 treatment had no effect on dysferlin ex-
pression in myotubes from dysferlinopathy patients but
increased dysferlin expression in muscle cultures from
carriers of one mutation in DYSF [8]. Although EB1089 is
50–200 times more potent than vitamin D3 [23], when
added to cultured myotubes from a dysferlinopathy pa-
tient it only produces a trend towards an increase in dys-
ferlin expression. Vitamin D3 acts through the Vitamin D
receptor and p38 MAPK and participates in differentiation
events in skeletal muscle cells [32]. Whether this effect is
dependent on dysferlin expression remains to be eluci-
dated. Moreover, EB1089 also presented a trend towards
decreased expression of myogenin when was combined
with proteasome inhibitors compared to the results of
treatment with a proteasome inhibitor alone. Although re-
sults were not statistically significant, this negative effect
could be explained by a negative regulation of myogenin
after EB1089 treatment. In previous studies, authors
showed that Vitamin D3 downregulates the expression of
myogenin both in vitro and in vivo [33–35]. These previ-
ous findings suggest that negative vitamin D response ele-
ments may be present in the promoter region of
myogenin, however those have not been identified [36].
We also analyzed the expression of TSP-1 in cell cul-
tures after treatment with proteasome inhibitors. TSP-1
is secreted in response to inflammation and multiple
factors modulate its release. It is expressed by endothe-
lial cells, fibroblasts, neutrophils, macrophages, T cells,
and myotubes [37]. We observed a significant decrease
in TSP-1 release when dysf mut/mut myotubes were ex-
posed to EB1089, oprozomib and the combination of
oprozomib or ixazomib and EB1089. The decrease in
TSP-1 levels could be the consequence of the trend to-
wards an increased expression of dysferlin in these con-
ditions. However, TSP-1 levels were significantly lower
when a combination of oprozomib and EB1089 was
added to the culture than when oprozomib was added
alone, suggesting that proteasome inhibitors and EB1089
act independently of dysferlin expression to reduce TSP-
1 release.
The reduced expression of TSP-1 observed after treat-
ment with EB1089 could be explained by mechanisms
independent of dysferlin expression. Amarasekera AT
et al. suggested that vitamin D supplementation reduces
TSP-1 levels in healthy individuals [38]. Moreover, it has
been studied that calcitrol, a vitamin D metabolite,
downregulates TSP-1 via the activation of the mitogen
activated protein kinase (MAPK) [39]. Therefore, EB1089
treatment could activate the MAPK pathway leading to
downregulation of TSP-1. This activation could constitute
an alternative mechanism to reduce TSP-1 levels that is
not linked to dysferlin expression.
The effect of proteasome inhibitors on TSP-1 could
also be explained by mechanisms non-related to dysfer-
lin expression, such as the inhibition of canonical NF-κB
Fig. 4 TSP-1 expression by dysf mut/mut myotubes treated with oprozomib, ixazomib and EB1089. a TSP-1 expression with treatment of
oprozomib at 10 nM and EB1089 100 nM was significantly decreased compared to C- (non-treated dysf mut/mut myotubes), and the
combination of both treatments was also significantly decreased compared to oprozomib treatment alone. b There were no significant
differences in TSP-1 levels between ixazomib and EB1089 compared to non-treated myotubes. However, the combination of both treatments
showed a significant reduction compared to non-treated myotubes. Data are represented as mean of 5 replicates ± standard deviation. Results
were statistically analyzed using one-way Anova followed by Tukey post hoc test. Statistical significance was set at p < 0.05. **p < 0.01; ***p < 0.0001
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signaling. NF-κB forms a dimer with IκB, an inhibitory
protein, which keeps the complex inactive in the cyto-
plasm. When signals activate this pathway, IκB is phos-
phorylated and degraded by the proteasome, releasing
the NF-κB to the nucleus where it regulates the tran-
scription of genes involved in the inflammatory
response. Proteasome inhibitors seem to decrease the
nuclear levels of NF-κB by avoiding the degradation of
IκB, hence decreasing NF-κB activity [40]. In effect, in
dysferlinopathy patients, damage-associated molecular
patterns (DAMPs) are released from damaged muscle
fibers, triggering inflammatory responses via activation
Fig. 5 Membrane repair and fusion index using oprozomib, ixazomib and EB1089 treatment. a Representative images of PI-positive nuclei and
MyHC positive myotubes after SDS treatment at 90 s and at 10min. The first 2 rows correspond to healthy myotubes and the last 2 rows
correspond to dysf mut/mut myotubes treated with oprozomib. b Quantification of IP-positive nuclei in myotubes from healthy controls and dysf
mut/mut myotubes treated with EB1089, oprozomib, and the combination of oprozomib 10 nM with EB1089at at 24 h. c Quantification of IP-
positive nuclei in myotubes from healthy controls and dysf mut/mut myotubes treated with EB1089, ixazomib, and the combination of ixazomib
100 nM with EB1089at at 8 h. Differences were not observed with any treatment. d Quantification of fusion index showed a statistically significant
decrease of MyHC positive myotubes compared to healthy myotubes. e Fusion index in dysf mut/mut myotubes treated with EB1089, oprozomib
at 10 nM and the combination of oprozomib 10 nM with EB1089 at 8 h did not show any difference compared to non-treated myotubes. f Fusion
index in dysf mut/mut myotubes treated with EB1089, ixazomib at 100 nM and the combination of ixazomib 100 nM with EB1089 at 24 h did not
show any difference compared to non-treated myotubes. Data are represented as mean of 3 replicates ± standard deviation. Results were
statistically analyzed using Mann-Whitney test to compare two groups and one-way Anova followed by Tukey post hoc test for multiple
comparisons. Statistical significance was set at p < 0.05. *p < 0.05; **p < 0.01; ***p < 0.0001
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of NF-κB [41]. We suggest that decreased NF-κB activity
by proteasome inhibitors could be another mechanism
involved in TSP-1 reduction and thereby reduce the in-
flammatory response.
We did not observe any sarcolemma repair when pro-
teasome inhibitors and EB1089 were added to the cul-
ture. We have previously reported that dysferlin mut/
mut cells fuse less efficiently than wild-type myoblasts.
We also demonstrated that dysferlin mut/mut myotubes
showed a reduced expression of myogenin in the nucleus
[14]. The experiments performed in the present study
confirm that fusion of myoblasts is impaired in dysferlin
mut/mut. Lack of dysferlin impaires sarcolemmal repair
both in myoblasts and myotubes therefore, we believe
that reduced fusion of myoblasts has no effect on the
membrane repair experiments. The trend towards in-
creased expression of dysferlin after treatment was not
strong enough to restore sarcolemma repair of damaged
myotubes.
Conclusions
In conclusion, we did not observe a significant increase of
dysferlin or myogenin in myotubes from a dysferlinopathy
patient when treated with EB1089, oprozomib and ixazo-
mib. However, we did observe a significant reduction in
TSP-1 levels. Targeting TSP-1 may constitute a thera-
peutic approach in patients carrying mutations affecting
proper folding of dysferlin since it would reduce inflam-
mation and avoid the undesirable side-effects reported in
patients with dysferlinopathy treated with prednisone.
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Additional file 1: Supplementary Figure 1.` Dysferlin and myogenin
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dysferlin with vitamin D3 and EB1089 treatment. Desmin was used as a
loading control. B) Representative full blot of myogenin and dysferlin
with oprozomib and EB1089 treatment. C) Representative full blot of
myogenin and dysferlin with ixazomib and EB1089 treatment.
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